E

Entrada Therapeutics

Develops intracellular therapeutics using endosomal escape

SEC Reporting & Technical Accounting Consultant

Full-Time
No salary listed
Senior
Bachelor's
Boston, MA, USA
Remote
AccountingFinancial Accounting

About the job

Requirements
  • A BA/BS degree with 7+ years of relevant experience or equivalent.
  • Experience working within a public company reporting structure is required.
  • Experience with public company reporting is required.
  • Strong proficiency with Microsoft Office products.
  • Strong technical accounting experience and research capabilities to determine accounting conclusions on key technical matters.
  • Extensive knowledge of SOX 404(a) controls and requirements.
  • Strong communication and organization skills.
  • Ability to perform effectively through organizational change.
Responsibilities
  • Lead the preparation of the Company’s Form 10-K.
  • Work closely with the Controller, Associate Director of SEC Reporting, COO, and Legal to ensure all areas of filings are complete and accurate.
  • Assist with the preparation of earnings releases and Form 8-Ks as needed.
  • Prepare and review supporting schedules related to external reporting.
  • Coordinate and manage the annual audit by external auditors and relationships with supporting consultants.
  • Manage reporting timelines and communicate them clearly to relevant internal and external stakeholders.
  • Assist with Audit Committee agenda oversight and preparation of meeting materials.
  • Support preparation of the proxy statement as time allows.
  • Manage the review of the Company annual tax provision and disclosures prepared by external consultants.
  • Support technical accounting research and document conclusions clearly, logically, and comprehensively.
  • Collaborate with consultants on complex and judgmental technical accounting areas to reach appropriate conclusions.
  • Support the accounting team and monthly close processes related to key accounting topics and areas of judgment, including revenue, leases, and investments.
  • Monitor emerging accounting pronouncements, determine their applicability, support implementation of new guidance, and communicate it to key stakeholders.
  • Manage the development, improvement, and implementation of accounting policies and procedures for all processes to ensure consistency in reporting.
  • Lead year-end SOX 404(a) compliance to support 10-K SOX conclusions.
  • Review SOC 1 reports for key vendors and service organizations.
  • Work with a third-party consultant to finalize SOX testing work.
  • Support Disclosure Committee agenda and related materials.
  • Determine financial statement materiality and related posting thresholds.
  • Complete other ad hoc projects with the Corporate Controller as needed.
Desired Qualifications
  • Prior experience with a top accounting firm and experience in a Life Science environment.
  • Experience with collaboration revenue recognition under ASC 606.
  • Knowledge of Accounting for Income Taxes under ASC 740.
  • Experience with Workiva.
  • A can-do attitude and appetite for learning new things, including support for research on new accounting pronouncements.

About the company

E

Entrada Therapeutics

View
Website

Entrada Therapeutics focuses on developing a new class of medicines to treat devastating diseases by delivering therapies inside cells. Its core technology, the Endosomal Escape Vehicle (EEV) platform, helps drugs escape from endosomes—cellular compartments that often trap or degrade treatments—so they can reach intracellular targets. The product pipeline centers on EEV-therapeutics, including candidates for Duchenne muscular dystrophy and other neuromuscular diseases, with ENTR-601-45 currently cleared by UK and EU regulators to begin clinical trials. What sets Entrada apart is its explicit emphasis on enabling intracellular delivery to access targets that were previously hard to treat, using a platform-agnostic delivery approach that can work with a range of therapeutics such as oligonucleotides. The company’s goal is to advance multiple EEV-therapeutics through clinical development to address rare and other hard-to-treat diseases and reach patients who need new treatment options.

Company Size

201-500

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2016

Get referred to Entrada Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ELEVATE-45-201 Cohort 1 readout arrives in October 2026 after clean safety monitoring.
  • Cohort 2 ENTR-601-44 enrollment finished in August 2026, with Q1 2027 data next.
  • The August 2026 long-term extension approval in the U.K. and EU extends DMD visibility.

What critics are saying

  • May 7, 2026 ENTR-601-44 dystrophin rose only 2.36%, crushing bullish expectations.
  • Cash fell to $223.0 million on June 30, 2026, funding only through Q3 2027.
  • ENTR-601-44 must beat Sarepta and Avidity quickly, or Entrada becomes a platform story gone flat.

What makes Entrada Therapeutics unique

  • EEV delivery targets intracellular cargo beyond standard exon-skipping competitors, as of 2026.
  • Entrada runs four DMD programs: ENTR-601-44, 45, 50, and 51.
  • Vertex partnership keeps VX-670 alive, with H2 2026 data expected.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • 401(k) Company Match
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

1%

2 year growth

3%
MarketBeat
Sep 3rd, 2026
Entrada Therapeutics (NASDAQ:TRDA) major shareholder sells $180,691.89 in stock.

Entrada Therapeutics (NASDAQ:TRDA) major shareholder sells $180,691.89 in stock. September 3, 2026 Key points. * Major shareholder Bioventures 2018 L.P. Mpm sold 25,131 Entrada Therapeutics shares at an average $7.19, generating $180,691.89. The sale reduced its ownership by 0.60%, leaving it with 4.18 million shares worth approximately $30.0 million. * The shareholder has also sold additional shares in a series of recent transactions, totaling more than 173,000 shares from August 27 through September 3. * Entrada shares fell 1.8% to $7.17, while the company recently reported a quarterly loss of $1.01 per share and revenue of $0.90 million, both weaker than analyst expectations. Analysts nevertheless maintain a "Moderate Buy" consensus with a $17.75 price target. * Five stocks we like better than Entrada Therapeutics. Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Bioventures 2018 L.P. Mpm sold 25,131 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $7.19, for a total value of $180,691.89. Following the completion of the sale, the insider owned 4,177,215 shares in the company, valued at approximately $30,034,175.85. The trade was a 0.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC. Bioventures 2018 L.P. Mpm also recently made the following trade(s): * On Thursday, September 3rd, Bioventures 2018 L.P. Mpm sold 32,263 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.17, for a total value of $231,325.71. * On Tuesday, September 1st, Bioventures 2018 L.P. Mpm sold 29,088 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.06, for a total value of $205,361.28. * On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total value of $309,370.41. * On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.01, for a total value of $26,168.33. * On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.20, for a total transaction of $280,238.40. Entrada Therapeutics stock down 1.8%. Entrada Therapeutics stock traded down $0.13 during trading on Thursday, reaching $7.17. The stock had a trading volume of 395,559 shares, compared to its average volume of 255,201. Entrada Therapeutics, Inc. has a 52-week low of $5.02 and a 52-week high of $16.45. The stock has a market cap of $279.20 million, a PE ratio of -1.81 and a beta of -0.25. The business has a 50 day moving average price of $7.08 and a 200 day moving average price of $9.20. Discover more Cryptocurrency News Compare Investment Apps Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.04). The firm had revenue of $0.90 million during the quarter, compared to analyst estimates of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. On average, equities analysts predict that Entrada Therapeutics, Inc. will post -4.03 EPS for the current fiscal year. Wall Street analysts forecast growth. Several analysts have recently weighed in on TRDA shares. Roth Capital reissued a "buy" rating and issued a $11.00 target price on shares of Entrada Therapeutics in a report on Wednesday, August 12th. Weiss Ratings raised shares of Entrada Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday. Guggenheim lowered their price target on Entrada Therapeutics from $20.00 to $17.00 and set a "buy" rating on the stock in a report on Monday, June 8th. Finally, HC Wainwright downgraded Entrada Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, May 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.75. Hedge funds weigh in on Entrada Therapeutics. Large investors have recently made changes to their positions in the stock. State of Wyoming purchased a new position in Entrada Therapeutics in the second quarter valued at about $37,000. Russell Investments Group Ltd. raised its holdings in Entrada Therapeutics by 72.7% during the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company's stock worth $51,000 after purchasing an additional 3,707 shares during the last quarter. Occudo Quantitative Strategies LP acquired a new stake in Entrada Therapeutics in the second quarter valued at $68,000. Jain Global LLC purchased a new position in shares of Entrada Therapeutics in the third quarter valued at $69,000. Finally, IHT Wealth Management LLC acquired a new stake in Entrada Therapeutics in the 2nd quarter valued at about $72,000. Hedge funds and other institutional investors own 86.39% of the company's stock. About Entrada Therapeutics. Entrada Therapeutics NASDAQ: TRDA is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs. The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Entrada Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entrada Therapeutics wasn't on the list. While Entrada Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you'll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Associated Press
Aug 5th, 2026
Entrada Therapeutics reports Q2 2026 results with multiple DMD data readouts ahead

Entrada Therapeutics reported second quarter 2026 financial results, highlighting multiple upcoming clinical data readouts for its Duchenne muscular dystrophy programmes. The company expects to report ELEVATE-44-201 Cohort 1 open-label data by year-end 2026 and Cohort 2 data in Q1 2027. ELEVATE-45-201 Cohort 1 results are anticipated in October 2026. Cash, cash equivalents and marketable securities totalled $223.0 million as of 30 June 2026, down from $295.7 million at year-end 2025. The company expects these funds to support operations into Q3 2027. Net loss was $42.8 million for the quarter, compared to $43.1 million in the same period last year. Research and development expenses decreased to $35.4 million from $37.9 million year-on-year. The company also received UK regulatory authorisation to initiate a Phase 1/2 study of ENTR-601-50 in DMD patients amenable to exon 50 skipping.

Yahoo Finance
May 9th, 2026
Entrada Therapeutics' DMD trial shows early functional gains with clean safety profile

Entrada Therapeutics has reported initial results from its phase I/II ELEVATE-44-201 trial of ENTR-601-44 in ambulatory Duchenne muscular dystrophy patients. The study showed favourable safety and tolerability, with only mild to moderate adverse events and no serious safety issues. The trial enrolled eight participants aged 6 to 17, randomised 3-to-1 to receive the 6 mg/kg dose or placebo. Headache was the most common adverse event, with no renal safety concerns observed. The company reported early functional benefits, including statistically significant improvement in time-to-rise velocity versus placebo and positive trends in the 10-metre walk/run test. Whilst plasma exposure was lower than expected, Entrada anticipates higher exon skipping and dystrophin levels in later cohorts. The company expects several clinical milestones in 2026 across its DMD programme.

BioSpace
May 7th, 2026
Entrada crashes as Duchenne therapy comes in 'below expectations' in early study.

Entrada crashes as Duchenne therapy comes in 'below expectations' in early study. May 7, 2026 | Entrada Therapeutics saw a 2.36% dystrophin increase in patients treated with its oligonucleotide asset - a number that fell short of the company's prior guidance of a double-digit improvement. Entrada Therapeutics' investigational oligonucleotide increased dystrophin concentrations in a Phase 1/2 Duchenne muscular dystrophy but not to the degree that analysts or the company had been expecting. In the first dosing cohort of the Phase 1/2 ELEVATE-44-201 trial, ENTR-601-44 elicited a 2.36% increase in normalized dystrophin levels in muscle tissue six weeks after the last dose, according to a Thursday release - well short short of Entrada's prior guidance of a double-digit jump. Shares of the Boston-based biotech plummeted 50% before the opening bell on Thursday, hitting $8.01 apiece. Oppenheimer analysts called ENTR-601-44's performance "disappointing," noting that the result puts Entrada's dystrophin benefit lower than that of competitor Avidity Biosciences. In a Thursday morning investor note, the firm pointed to a September 2025 readout in which Avidity reported an approximately 25% increase in the protein for its own oligonucleotide therapy del-zota after one year of treatment. Importantly, no trials directly comparing the two have been conducted. William Blair had a similar assessment of Entrada's readout. "Measurements of dystrophin protein expression after ENTR-601-44 treatment, the main efficacy-based endpoint of focus for investors, showed a 2.36% increase from baseline, which missed our base case of 10% and also management's expectations," the analysts wrote in a Thursday note. On a more positive note, Oppenheimer homed in on ENTR-601-44's effects on time-to-rise (TTR) velocity, a robust measure of functional performance that, according to Entrada, is "used as an early prognostic factor for disease progression and loss of ambulation." Thursday's readout demonstrated an average TTR improvement of 0.08 in patients treated with Entrada's molecule. Oppenheimer called this magnitude of effect "clinically significant" and noted it is "larger than competitors, suggesting a potential clinical benefit." As for safety, Entrada touted a favorable overall profile for a 6-mg/kg dose of ENTR-601-44, with no serious side effects or adverse events triggering discontinuation. Oppenheimer found the "clean" safety profile encouraging, explaining that it "allows for dose escalation to 12-18mg/kg that can ultimately deliver a competitive profile." With Thursday's data, ELEVATE-44-201 will continue on to its second patient cohort, which will receive a 12-mg/kg dose of the drug. Dosing for this leg of the study has started, with data expected by year-end. ENTR-601-44 is an oligonucleotide therapy that binds to exon 44 in the dystrophin pre-mRNA, allowing the cell's splicing machinery to skip over the faulty exon, according to Entrada's website. This ultimately results in a shorter but functional dystrophin protein, helping maintain the function and integrity of muscle cells, which in patients with Duchenne muscular dystrophy (DMD) otherwise undergo progressive degeneration. Common complications of the disease include heart and lung problems, often leading to death. Sarepta Therapeutics' Amondys 45 and Vyondys 53 work similarly to ENTR-601-44, removing faulty exons from the final mRNA transcript and facilitating the expression of truncated but functional dystrophin. In November last year, the drugs failed their confirmatory Phase 3 study, unable to elicit significant motor improvements in patients over placebo. Sarepta has nevertheless submitted supplemental applications to the FDA for both drugs. Vyondys 53 was first approved in 2019 and Amondys 45 in 2021, both under the agency's accelerated pathway.

Associated Press
May 7th, 2026
Entrada Therapeutics reports Q1 2026 results with positive DMD trial data and $255M cash runway into Q3 2027

Entrada Therapeutics reported positive topline results from Cohort 1 of its ELEVATE-44-201 study in Duchenne muscular dystrophy, showing favourable safety and tolerability alongside early functional benefits. The study of ENTR-601-44 at 6 mg/kg demonstrated statistically significant improvement in Time to Rise velocity, with all adverse events classified as mild or moderate. The company reported cash, cash equivalents and marketable securities of $255 million as of 31 March 2026, providing runway into the third quarter of 2027. Entrada plans to report ELEVATE-45-201 Cohort 1 data in mid-2026 and ELEVATE-44-201 open-label period and Cohort 2 data by year-end 2026. Net loss for the first quarter was $39.7 million, compared to $17.3 million in the same period last year.